To study the effect of changes in plasma nonesterified fatty acid concentration on suppression of hepatic glucose production by insulin eight Type 2 (non-insulin-dependent) diabetic patients participated in three euglycaemic, hyperinsulinaemic (108pmol-m 2 ~.min 1) clamp studies combined with indirect calorimetry and infusion of [3-3H] -glucose and [1-~4C]palmitate; (1) a control experiment with infusion of NaC1 154mmol/1, (2) heparin was infused together with insulin, and (3) an antilipolytic agent, Acipimox, was administered at the beginning of the experiment. Six healthy volunteers participated in the control experiment. Plasma non-esterified fatty acid concentrations during the insulin clamp were in diabetic patients: (1) 151 + 36 gmol/1, (2) 949 + 178 Bmol/1, and (3) 65 _+ 9 Bmol/1; in healthy control subjects 93 +13 ~tmol/1. Non-esterified fatty acid transport rate, oxidation and non-oxidative metabolism were significantly higher during the heparin than during the Acipimox experiment (p < 0.001). Suppression of hepatic glucose production by insulin was impaired in the diabetic compared to control subjects (255 +42 vs 51 • 29 ~tmol/min, p < 0.01). Infusion of heparin did not affect the suppression of hepatic glucose production by insulin (231_+ 49 Bmol/min), whereas Acipimox significantly enhanced the suppression (21+ 53 gmol/min, p < 0.001 vs 154 mmol/1 NaC1 experiment). We conclude that insulinmediated suppression of hepatic glucose production is not affected by increased non-esterified fatty acid availability. In contrast, decreased non-esterified fatty acid availability enhances the suppression of hepatic glucose production by insulin.
Impaired suppression of hepatic glucose production (HGP) by insulin represents one of the manifestations of insulin resistance in patients with Type 2 (non-insulindependent) diabetes [1, 2] . Several [2] [3] [4] [5] [6] [7] , although not all [8] authors have reported resistance to suppression ofnonesterified fatty acid (NEFA) metabolism by insulin in Type 2 diabetes. Enhanced availability of NEFA could in a diabetic individual provide the basis for the glucose/fatty acid cycle first proposed by Randle and co-workers [9] . In accordance with this hypothesis increased oxidation of NEFA leads to decreased oxidation of glucose and to insulin resistance. Although the liver was not included in the original Randle hypothesis, the question arises, whether there is a connection between HGP and NEFA metabolism in diabetic patients, and whether increased availability of NEFA is involved in the pathogenesis of hepatic insulin resistance. Early in vitro experiments with perfused rat liver have shown that increased NEFA availability stimulates gluconeogenesis from lactate [10] , alanine [11] and pyruvate [12] . This has been attributed to stimulation of pyruvate carboxylase, one of the key enzymes in gluconeogenesis [13] . The view has, however, been challenged by others [14] . In healthy man elevation of plasma NEFA concentration by lipid and heparin infusion stimulates HGP under conditions of hypoinsulinaemia and hyperglycaemia [15, 16] . In addition, lowering ofptasma NEFA by sodium acetoacetate infusion suppresses HGP under conditions ofinsulinopoenia, combined with normo-or hyperglycaemia [16] . In obese individuals increased plasma NEFA availability blunts the inhibitory effect of insulin on HGP [17] . However, there are no data on the effect of NEFA on HGP in diabetic individuals.
This study was therefore undertaken to evaluate the effects of increased and decreased plasma NEFA availability on insulin-mediated suppression of HGP in patients with Type 2 diabetes.
Subjects and methods
Eight patients with Type2 diabetes participated in the study (Table 1) . Five patients were treated with sulfonylureas and three patients with diet alone. The patients treated with sulfonylurea dis- 
Experimental design
Each patient participated with 2-3 week intervals in random order in three euglycaemic, hyperinsulinaemic clamp studies in combination with indirect calorimetry and infusion of [3-3H] glucose and [154C]palmitate. Study I was a control study with infusion of NaC1 154 mmot/1 together with insulin; during study 2 hepariu was infused as a primed (200 IU) continuous (30 IU/min) infusion together with insulin to maintain plasma NEFA concentration at baseline levels despite insulin infusion; during study 3 Acipimox 500 mg (5-methylpyrazine-carboxylic acid 4-oxide, Farmitalia Carlo Erba, Milan, Italy) was given orally 120 rain before starting the insulin infusion to lower the plasma NEFA concentration. The non-diabetic subjects participated only in the control study. Four patients participated in a fourth study, in which heparin infusion was combined with Acipimox administration (protocols 2 and 3 combined). The experiments were begun at 07.30 hours after a 12 h fast, with the subject in the supine position.
Euglycaemic insulin clamp
Insulin sensitivity and glucose metabolism were measured using the euglycaemic hyperinsulinaemic clamp technique [18] . After obtaining three baseline samples for determination of glucose and insulin, a primed-constant infusion of short-acting human insulin (Actrapid Human, Novo Industry, Copenhagen, Denmark) was administered at a rate of 108 pmol. m 2 . min 1 for 120 min. The plasma glucose concentration was determined at 5 min intervals, and an infusion of 20% glucose was adjusted to maintain the plasma glucose concentration constant at the basal level. Hepatic glucose production and plasma NEFA transport rates were measured by the isotope-dilution technique. Hepatic glucose production was measured using [3-3H]glncose (7.8 Ci/mmol, Amersham International, Bucks, UK) administered as a primed (0.25 gCi) constant (0.25 }.tCi/min) infusion for 150 min before and throughout the insulin damp. In four patients the study was repeated administering [3-3H] glucose with the glucose infusion. To maintain plasma [3 JH]glucose specific activity constant during infusion of insulin, the [3-3H]glucose infusion was step-wise diminished to 25% during the first 30 min of the insulin clamp. To ensure constancy of plasma [3-3H] glucose specific activity during the entire insulin damp, [3-3H] glucose was added to the exogenously infused "cold" glucose.
C. Saloranta et al.: Modulation of hepatic glucose production by NEFA The amount of [3-3H] glucose added to the glucose solution was calculated according to the method of Norwich [19] , assuming that the baseline hepatic glucose production was 11 gmol. kg 1. min 1. To trace plasma NEFA transport and oxidation rates a primed (3 Indirect calorimetry was performed in the basal period and during the last 60 min of the insulin clamp to estimate net rates of carbohydrate and lipid oxidation [21] . A computerized, open-circuit system was used to measure gas exchange through a transparent plastic canopy (Deltatrac, Datex, Helsinki, Finland) which was placed over the subject's head [22] . Air flow was measured by the air-dilution method, carbon dioxide concentration by a conventional infrared detector, and oxygen concentration by a fast differential paramagnetic oxygen sensor. The monitor has a precision of 2.5% for oxygen consumption and 1.0% for carbon dioxide production. Protein oxidation was estimated from urinary excretion of urea before and during the insulin clamp.
Assays
Plasma glucose was assayed with a glucose oxidase method adapted for the Beckman Glucose Analyzer II (Beckman Instruments, Fullerton, Calif., USA). [3-3H]glucose radioactivity was measured in duplicate on supernatant of 0.5 N perchloric acid extracts of plasma samples, after evaporation of radiolabelled water. Glycohaemoglobin concentration in blood was measured by microcolumn chromatography (Isolab, Akron, Ohio, USA). The reference level for the assay was 5-7%. Serum insulin was measured by a double-antibody radioimmunoassay (Pharmacia, Uppsala, Sweden). The urinary excretion of urea was measured enzymatically (bioMerieux, Marcy-l'Etoile, France). Plasma NEFA were measured with the microfluorometric method by Miles et al. [23] . The specific activity of plasma [1JeC]NEFA was measured as previously described [2, 24] . One ml of plasma was extracted with 10 ml of Dole's solution. NEFA were isolated from the lipid phase using 0.02 N NaOH, and re-extracted with heptane after acidification. After evaporation to dryness the extract was dissolved in scintillation liquid (Aquasol; New England Nuclear) and counted in a liquid scintillation counter (Wallac, Turku, Finland). The plasma [1-14C]NEFA specific activity was then calculated by dividing the t4C-radioactivity in i ml of plasma by the plasma NEFA concentration. The specific activity of [t4C]carbon dioxide in expired air was determined by measuring the radioactivity of i mmol expired carbon dioxide in a scintillation counter (Wallac). Total [14C]carbon dioxide expired per min was determined by multiplying [14C]carbon dioxide specific activity by the total carbon dioxide production rate measured by indirect calorimetry.
Calculations
Basal HGP was calculated by dividing the [3-3H] [3-3H] glucose specific activity exists, and the rate of glucose appearance was calculated using the model described by Radziuk [25] . At high rates of glucose uptake, this model, as the classical model of Steele [26] , is known to produce negative estimates of HGR Negative numbers of HGP were observed when Acipimox was administered prior to the insulin infusion. When adding [3-3H] glucose to the variable exogenous glucose infusion, the plasma [3-3H]glucose specific activity was maintained constant throughout the entire insulin clamp, and no negative numbers of HGP were observed. The infusion rate of exogenous glucose was integrated over 20 min intervals and subtracted from the total rate of glucose appearance to obtain the HGP rate. Total body glucose metabolism was calculated by adding the mean rate of HGP (if a positive number) during the last 60 min of the insulin clamp to the mean glucose infusion rate during the same period. Non-oxidative glucose metabolism, which mainly reflects glycogen synthesis [27] , was calculated as the difference between total body glucose metabolism and glucose oxidation determined by indirect calorimetry. Net glucose and lipid oxidation rates were calculated from indirect calorimetric measurements. The constants used to calculate glucose, lipid and protein oxidation from gas exchange data and urinary urea excretion have been previously published [20] . To allow direct comparison with plasma NEFA oxidation net lipid oxidation data were expressed in molar units by using the molecular weight of palmitate (mol. wt. = 256).
Plasma NEFA transport rate was calculated by dividing the infusion rate of [14C]palmitate by the steady-state plasma NEFA specific activity during the last 30 min of the equilibration period and the last 30 min of the insulin clamp. Although palmitic acid accounts for only 411 about 30% of plasma NEFA, the fractional turnover rate of palmitate is very similar to that of total NEFA, and therefore labelled palmitate can be used to trace total plasma NEFA [28] [29] [30] . Plasma NEFA oxidation rate was calculated by dividing the [~4C]carbon dioxide specific activity in expired air by the plasma NEFA specific activity and a factor k, which takes into account the incomplete recovery of labelled [~4C]carbon dioxide from the bicarbonate pool [20, 31] . Plasma NEFA oxidation rate per rain = [I4C[carbon dioxide specific activity x VCO2 (k x [14C]NEFA specific activity), where VCO2 = total CO2 production per rain and k = 0.81.
Non-oxidative plasma NEFA metabolism was calculated as the difference between plasma NEFA transport rate and oxidation [2] . The difference between total body net lipid oxidation measured by indirect calorimetry and plasma NEFA oxidation measured using [1-14C] palmitate is referred to as intracellular lipid oxidation.
Statistical analysis
Data are presented as mean + SEM. Statistical analysis has been performed using a computer program (The System for Statistics, SYSTAT, Inc., 1987, Evanston, Ill., USA). Differences between groups were tested by unpaired t-test, and differences within groups by paired t-test. Relationships between variables were calculated by pair-wise Spearman rank correlations.
Results
In diabetic subjects serum insulin concentrations during the clamp were 213 _+ 11,210 _+ 14 and 227 _+ 16 pmoI/1 during 154 mmol/1NaC1, heparin and Acipimox experiments, respectively. The plasma glucose concentrations were clamped at the basal levels, i.e. 7.5 _+ 0.8, 7.9 + 0.7 and 8.1 + 0.8 retool/l, respectively. In healthy control subjects the corresponding serum insulin and plasma glucose concentration was 187 _+ 19 pmol/1 and 5.2 + 0.2 mmol/1, respectively (Fig. 1 ).
Lipid metabolism
In diabetic patients, baseline plasma NEFA concentrations were similar during 154mmol/1 NaC1 (719 + 53 gmol/1) and heparin (747 + 53 gmol/1) protocols, and did not differ from healthy control subjects (690 + 78 gmol/1). Acipimox lowered basal plasma NEFA to 150 + 36 gmol/1 (p < 0.001 vs 154 mmol/1 NaC1 and heparin). During the insulin clamp, plasma NEFA declined to 151 + 36 ~tmol/l in the 154 mmol/1 NaC1 study, but was maintained at 949 + 178 gmol/1 when heparin was infused with insulin (p < 0.001 vs 154 mmol/1 NaC1 experiment). After Acipimox, plasma NEFA declined to 65 + 9 gmol/1 (p < 0.05 vs 154 mmol/1 NaC1 experiment) during the insulin clamp, which was not significantly different from the concentration in healthy control subjects (96 + 13 gmol/1) (Fig. 1) .
Plasma NEFA transport rate (Fig. 2) . In the diabetic patients, basal plasma NEFA transport rate did not differ between 154 mmol/1 NaC1 and heparin and was not significantly different from basal plasma NEFA transport rate measured in healthy subjects. After Acipimox, basal plasma NEFA transport rate was reduced by 70% compared Modulation of hepatic glucose production by NEFA tion rate measured in control subjects. After Acipimox the basal plasma NEFA oxidation rate declined by 65% in the diabetic subjects (p < 0.001 vs 154 mmol/1 NaC1 and heparin experiments), reflecting the changes in plasma NEFA concentration. During the 154 mmol/1 NaC1 experiment, insulin suppressed plasma NEFA oxidation rate by 65% in diabetic patients. During heparin infusion, plasma NEFA oxidation was maintained at its basal rate even during the insulin clamp. After Acipimox, plasma NEFA oxidation rate was further reduced by 15% during insulin infusion, which was not significantly different from the NEFA oxidation rate seen in control subjects.
Non-oxidative plasma NEFA metabolism (Fig. 2) . There was no difference in the basal rate of non-oxidative plasma NEFA metabolism between 154 mmoI/1NaC1 and heparin experiments in diabetic subjects, neither was there any significant difference between diabetic and control subjects. However, after Acipimox, the basal rate of nonoxidative NEFA metabolism declined by 70% (p < 0.001 vs 154 retool/1NaC1 and heparin). During the 154 mmol/1 NaC1 experiment, insulin suppressed non-oxidative plasma NEFA metabolism by 70%. When heparin was infused together with insulin, non-oxidative NEFA metabolism was maintained at its basal rate. However, after Acipimox was given, non-oxidative NEFA metabolism was further suppressed by 15%, which was not significantly different from the suppression observed in control subjects. (Fig. 2) . The basal rate of total body net lipid oxidation, as measured by indirect calorimetry, was similar in both control and diabetic subjects. After Acipimox, there was a small decrease in the basal rate of net lipid oxidation (20%, p < 0.05 vs heparin). During the 154 retool/1NaC1 experiment, insulin suppressed net lipid oxidation by 30% in diabetic subjects. Heparin partially prevented the suppressive action of insulin on net lipid oxidation (p < 0.05 vs saline). After Acipimox, net lipid oxidation fell further by 35% during insulin infusion, which was not significantly different from the suppression seen in control subjects.
Net lipid oxidation
to 154 mmol/1 NaC1 and heparin experiments (p < 0.001).
During the 154 mmol/1 NaC1 experiment, insulin suppressed plasma NEFA transport rate by 70% in diabetic subjects. When heparin was infused with insulin, the plasma NEFA transport rate was maintained at the basal level. However, after Acipimox administration the plasma NEFA transport rate was further suppressed by 15%, which was not significantly different from the suppression seen in healthy subjects.
Plasma NEFA oxidation rate (Fig. 2) . The basal plasma NEFA oxidation rate was not significantly different between the 154 mmol/1 NaC1 and heparin experiments, neither did the values significantly differ from the oxida-
Glucose metabolism
Hepatic glucose production (Fig. 3) . In the diabetic subjects, basal HGP did not differ between 154 mmol/1NaC1, heparin and Acipimox experiments, but was slightly higher than in control subjects (NS). During the insulin clamp, HGP was less suppressed in diabetic (255 + 42 Bmol/min during the 154 mmol/1 NaC1 experiment) than in control subjects (51+29gmol/min, p < 0.01). Suppression of HGP by insulin was not altered by infusion of heparin in the diabetic subjects (231 + 49 gmol/min). However, after Acipimox administration, suppression of HGP by insulin was significantly enhanced to 21 + 53 gmol/min (p < 0.001 vs 154 mmol/1 NaC1 and heparin experiments), which was no longer different from the suppression seen in control subjects. Adding [3-3H] glucose to the exogenous glucose infusion in four of the patients yielded similar results. Basal HGP did not differ between 154 mmol/1 NaC1 To exclude the possibility that enhanced suppression of HGP was due to Acipimox itself rather than a consequence of the decline in plasma NEFA availability, four patients participated in one further experiment, in which Acipimox administration was combined with heparin infusion. During this protocol, plasma NEFA concentration remained at the basal level during the insulin clamp 413 (894 + 316 gmol/1), and no enhanced suppression of HGP by insulin was observed (204 _+ 79 gmol/min). (Fig. 3) . In the post-absorptive state glucose disposal equals hepatic glucose production, and was calculated from the tracer data. In the diabetic subjects insulin-stimulated glucose metabolism was similar during 154 mmol/1 NaC1 and heparin experiments, and did not differ from the rate observed in control subjects. However, Acipimox administration increased insulinstimulated total glucose metabolism by 24% compared with the 154 mmol/1NaC1 experiment (p < 0.05).
Total body glucose disposal
Glucose oxidation (Fig.3) . In the diabetic patients the basal rate of glucose oxidation did not differ between the 154 mmol/1 NaC1 and heparin experiments, and was not significantly different from the rate observed in control subjects. However, Acipimox administration significantly increased basal glucose oxidation (p < 0.01 vs 154 mmol/1 NaC1 experiment). Insulin-stimulated glucose oxidation was similar in control and diabetic subjects during the saline experiment. Heparin infusion slightly decreased (p <0.05 vs 154mmol/1 NaC1), whereas Acipimox increased (p <0.01 vs 154mmol/1 NaC1) the rate of insulin-stimulated glucose oxidation. (Fig. 3 ). There were no differences in insulin-stimulated non-oxidative glucose disposal between control and diabetic subjects.
Non-oxidative glucose metabolism
Protein oxidation. There was no difference in protein oxidation during the insulin clamp between control (0.54 + 0.09 mg.kg-1 min-J) and diabetic subjects (0.57 + 0.07, 0.62 + 0.05 and 0.64 + 0.06 rag. kg-~-min-~ in the 154 mmol/1NaC1, heparin and Acipimox experiments, respectively).
Discussion
Fasting hyperglycaemia in a diabetic individual is attributed to enhanced production of glucose in the liver [32] . As most Type 2 diabetic patients present with elevated insulin concentrations in the fasting state, this would imply that the liver is resistant to the suppressive action of insulin. The majority of this glucose overproduction can be accounted for by an increased rate of gluconeogenesis [33] . The diabetic subjects in the present study displayed a slightly elevated basal rate of HGR which was less suppressed by insulin than in control subjects. The patients thereby presented one of the characteristic disturbances of Type 2 diabetes, i. e. hepatic insulin resistance.
In contrast, insulin-stimulated glucose disposal was not significantly impaired in the diabetic compared with the control subjects. This may be partially explained by higher plasma glucose concentration in the diabetic than in control subjects; the mass action effect of higher glucose concentration could overcome a possible defect in glucose uptake. The insulin level in this study, however, was chosen to detect differences in the action of insulin on HGR and was therefore not high enough to normalize the plasma glucose concentration in the diabetic subjects.
The rates of NEFA and lipid metabolism in the basal state and during the insulin clamp were slightly (20-30%) higher in the diabetic than in the control subjects. This is in keeping with several previous reports [2] [3] [4] [5] [6] [7] suggesting that the lipid metabolism is resistant to the action of insulin in Type 2 diabetes. In this study, manipulation of plasma NEFA concentration by heparin and Acipimox was followed by corresponding changes in total, oxidative and non-oxidative NEFA metabolism. Thus, when plasma NEFA concentrations remained high due to heparin infusion, insulin did not suppress NEFA metabolism, implying that insulin regulates NEFA metabolism only by its antilipolytic effect. The changes in total body net lipid oxidation were less marked. This discrepancy between plasma NEFA oxidation and net lipid oxidation suggests that direct intracellular NEFA oxidation, which is measured by indirect calorimetry but not by the palmitate tracer, is less influenced by changes in plasma NEFA concentration than is oxidation of NEFA's equilibrating with the plasma pool. Plasma NEFA oxidation comprised about 40% of total body net lipid oxidation. This is consistent with the results of Dagenais et al. [34] , who measured NEFA uptake and oxidation in resting human forearm by using labelled oleic acid.
Increased NEFA availability induced by heparin did not alter suppression of HGP by insulin. The data thus suggest that under these conditions, elevation of plasma NEFA concentrations within the physiological range are unlikely to explain the hepatic insulin resistance. Indirect support for an interaction between NEFA and HGP has been derived from studies demonstrating a positive correlation between NEFA or lipid oxidation and HGP rates [3, 36, 37] . In addition, under experimental hyperglycaemia and hypoinsulinaemia in healthy man, infusion of Intralipid impairs the suppressive action of insulin on HGP [15] . Similarly, acute elevation of plasma NEFA by Intralipid in obese subjects leads to hepatic insulin resistance [17] . In contrast to these reports, we studied diabetic patients during physiologic hyperinsulinaemia and physiologic elevations of plasma NEFA concentrations induced by heparin.
When plasma NEFA levels were lowered by Acipimox, the sensitivity of the liver to insulin was increased. As negative estimates of HGP were obtained in this experiment, the study was repeated adding tracer to the glucose infusion in some of the patients. Even using this approach, Acipimox enhanced the sensitivity of the liver to insulin. Whether this is a consequence of the decline in plasma NEFA or an effect of Acipimox itself was evaluated by an additional experiment, combining heparin infusion with Acipimox, resulting in unchanged plasma NEFA concentration during the insulin clamp. In this experiment, the suppressability of HGP by insulin was similar to that during heparin infusion alone, indicating that Acipimox has no other effect on HGP than the effect mediated by its antilipolytic effect. This is supported by in vitro experiments using perfused rat liver, in which nicotinic acid administration without change in NEFA availability has no effect on gluconeogenesis [38] .
C. Saloranta et al.: Modulation of hepatic glucose production by NEFA Why is there an effect of decreased but not of increased NEFA concentration on HGP? If elevated NEFA concentrations stimulate HGR this should have been observed during the heparin experiment, during which plasma NEFA levels were 800 gmol/1 higher than during the 154 mmol/1 NaC1 experiment. Do NEFA have a restraining effect on the suppression of HGP by insulin, which is released below a certain NEFA threshold? Increasing plasma NEFA levels above this threshold would in that case have no further effect on HGR In support of this, elevation of plasma NEFA by heparin in normal subjects does not lead to impaired suppression of HGP by insulin [39] .
In conclusion, the results imply that plasma NEFA availability at least partially modulates insulin-mediated regulation of HGP in Type 2 diabetes. Increased plasma NEFA concentrations do not affect the inhibitory effect of insulin on HGR However, decreasing plasma NEFA availability increases the sensitivity of the liver to insulin.
